Immunomodulatory synergy by combining atorvastatin and rapamycin in the treatment of experimental autoimmune encephalomyelitis (EAE)

Journal of Neuroimmunology

Volumn 250, Issue 1-2, 2012, Pages 9-17

  Li, Zhenfei ^a   Chen, Liping ^a   Niu, Xiaoli ^a   Liu, Jia ^a   Ping, Man ^a   Li, Ru ^a   Xie, Xiaohua ^a   Guo, Li ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Combination therapy; EAE; ERK MAPK; Multiple sclerosis; T regulatory cells

Indexed keywords

ATORVASTATIN; INTERLEUKIN 17; MITOGEN ACTIVATED PROTEIN KINASE; RAPAMYCIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ FOXP3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVATION; FEMALE; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; BLOTTING, WESTERN; CYTOKINES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLOW CYTOMETRY; HEPTANOIC ACIDS; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED C57BL; PYRROLES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIROLIMUS; SPINAL CORD; T-LYMPHOCYTES;

EID: 84864859746     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.05.008     Document Type: Article

References (45)

1. Abraham R.T., Wiederrecht G.J. Immunopharmacology of rapamycin. Annu. Rev. Immunol. 1996, 14:483-510.
2. Aktas O., et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 2003, 197:725-733.
3. Amadi-Obi A., Yu C.R., Liu X., Mahdi R.M., Clarke G.L., Nussenblatt R.B., Gery I., Lee Y.S., Egwuagu C.E. T(H)17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 2007, 13:711-718.
4. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 2006, 177:8338-8347.
5. Branisteanu Dumitru D., et al. Synergism between sirolimus and 1,25-dihydroxyvitamin D3 in vitro and in vivo. J. Neuroimmunol. 1997, 79:138-147.
6. Brereton Corinna F., Sutton Caroline E., Lalor Stephen J., Lavelle Ed C., Mills Kingston H.G. Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease. J. Immunol. 2009, 183:1715-1723.
7. Carracedo A., Ma L., Pandolfi P.P., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
8. Connor P.O., Wolinsky J.S., Freedman M.S., et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 2011, 365:1293-1303.
9. Donia M., Mangano K., Nicoletti F. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. J. Autoimmun. 2009, 33:135-140.
10. Dunn S.E., Youssef S., Goldstein M.J., et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J. Exp. Med. 2006, 203:401.
11. Eisenberg S., Henis Y.I. Interactions of Ras proteins with the plasma membrane and their roles in signaling. Cell. Signal. 2008, 20:31-39.
12. Esposito M., Ruffini F., Bellone M., Gagliani N., Battaglia M. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J. Neuroimmunol. 2010, 220:52-63.
13. Filippini G., et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003, 361:545-552.
14. Giovannoni G., Commi G., Cook S., et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:416-426.
15. Hartung H.P., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025.
16. Johnson K.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995, 45:1268-1276.
17. Jorritsma P.J., Brogdon J.L., Bottomly K. Role of TCR-induced extracellular signal-regulated kinase activation in the regulation of early IL-4 expression in naive CD4+ T cells. J. Immunol. 2003, 170:2427-2434.
18. Kagami S., Nakajima H., et al. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3 regulatory T cells. Int. Immunol. 2009, 21:679-689.
19. Kahan B.D., Camardo J.S. Rapamycin: clinical results and future opportunities. Transplantation 2001, 72:1181-1193.
20. Kappos L., Barkhof F., Desmet A. The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomized, controlled, clinical trial. J. Neurol. 2005, 252:S46.
21. Kappos L., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:387-401.
22. Kretzschmar M., Doody J., Timokhina I., Massagué J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 1999, 13:804-816.
23. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 2000, 6:1399-1402.
24. Li L., Godfrey W.R., Porter S.B., Ge Y., June C.H., Blazar B.R., Bussiotis V.A. CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood 2005, 9:3068-3073.
25. Loenen J.J., Koenen H.J., van Rijssen E., Joosten I. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+CD25+FoxP3+ T cells. Bone Marrow Transplant. 2007, 39:537-545.
26. Lopes C.T., Pletiskaitz T.M.F., Bueno V. Sirolimus in combination with FTY720: analysis of urinary and serum parameters. Transplant. Proc. 2010, 42:582-584.
27. McCarey D.W., et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363:2015-2021.
28. Mor A., Keren G., Kloog Y., George J. N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells. Eur. J. Immunol. 2008, 38:1493-1502.
29. Munari L.M., Filippini G. Lack of evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol. 2004, 3:641.
30. Neuhaus O., et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 2002, 59:990-997.
31. Polman C.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:899-910.
32. Procaccini C., Rosa V.D., Galgani M., et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 2010, 33:929-941.
33. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 2003, 35:7S-14S.
34. Soos J.M., et al. Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J. Immunol. 2002, 169:2231-2235.
35. Steinman L., Zamvil S.S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 2005, 26:565-571.
36. Strauss L., Whiteside T.L., Knights A., Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J. Immunol. 2007, 178:320-329.
37. Stüve O., Youssef S., Zamvil S.S. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J. Clin. Invest. 2006, 116:1037-1044.
38. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661. The IFN-β Multiple Sclersosis Study Group.
39. Tone Y., Furuuchi K., Kojima Y., Tykocinski M.L., Greene M.I., Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat. Immunol. 2008, 9:194-202.
40. Vollmer T., et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004, 363:1607-1608.
41. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 2006, 354:924-933.
42. Youssef S., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84.
43. Zamvil S.S., Steinman L. Cholesterol lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. Neurology 2002, 59:970-971.
44. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 1996, 65:241-269.
45. Zhang X., Jin J.P., Peng X.Y., Markovic P.S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J. Immunol. 2008, 180:6988-6996.